Literature DB >> 7976083

Effects of cis- and trans-urocanic acids on the secretion of interleukin-1 beta and tumour necrosis factor-alpha by human peripheral blood monocytes.

J K Laihia1, C T Jansén, J Uksila, J Punnonen, K Neuvonen, P Pasanen, P Ayräs.   

Abstract

In order to investigate the mechanism of urocanic acid (UCA)-mediated immune modulation, we studied the effect of cis- and trans-UCA on interleukin-1 beta and tumour necrosis factor-alpha production by human peripheral blood monocytes, using immunospecific ELISA techniques. Trans-UCA augmented the interleukin-1 beta production and inhibited tumour necrosis factor-alpha production in a dose-dependent manner, whereas cis-UCA had no effect on the secretion of these cytokines by phorbol myristate acetate or lipopolysaccharide-stimulated monocytes. This is a novel example of trans-UCA mediating a biological effect, a finding earlier reported for cyclic adenosine monophosphate up-regulation in human fibroblasts by Palaszynski and coworkers and for human natural killer cell inhibition by ourselves. Our data suggest an important role for trans-UCA as an immunomodulator in the skin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7976083     DOI: 10.2340/0001555574266268

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

1.  Urocanic acid suppresses the activation of human neutrophils in vitro.

Authors:  K Kivistö; K Punnonen; J Toppari; L Leino
Journal:  Inflammation       Date:  1996-10       Impact factor: 4.092

2.  Lack of metallothionein-I and -II exacerbates the immunosuppressive effect of ultraviolet B radiation and cis-urocanic acid in mice.

Authors:  V E Reeve; N Nishimura; M Bosnic; A E Michalska; K H Choo
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

3.  Expression of CD80 (B7/BB-1) and CD28 in human white blood cells treated with urocanic acid.

Authors:  J K Laihia; J Uksila; M Luhtala; C T Jansén
Journal:  Arch Dermatol Res       Date:  1996-09       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.